Active Clinical Trials

Active Clinical Trials at Advanced Heart and Vascular Institute

The Advanced Heart and Vascular Institute (AHVI) is at the forefront of medical research, dedicated to advancing cardiovascular care through innovative clinical trials. This page lists our current enrolling cardiology and vascular studies, providing patients with access to next-generation therapies. Information updated as of June 2026.

Peripheral Artery Disease (PAD)

ROXI-PALISADE

Now enrolling

View Details
  • Adults with peripheral artery disease (PAD) who have recently had a successful procedure to restore blood flow in the legs
  • Investigational medication given by injection under the skin every two weeks, compared with placebo
  • Now enrolling at Advanced Heart and Vascular Institute of Hunterdon
Heart with electrocardiogram pulse line

Cardiology / Atrial Fibrillation

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation (REACT-AF)

Device Trial | John Hopkins & NIH

View Details
  • Adults 18–85 with Paroxysmal Atrial Fibrillation
  • At least one cardiovascular risk factor
  • Actively taking a DOAC
Lipoprotein(a) molecule illustration

Lipoprotein(a) / Lp(a)

OCEAN(a)-PreEvent – Olpasiran Trials of Cardiovascular Events And LipoproteiN(a)

Phase III | AMGEN

View Details
  • Age ≥50 years
  • Lp(a) ≥ 200 nmol/L during screening
  • Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
Small interfering RNA double helix illustration

Hypertension

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease (ZENITH)

Phase III | Alnylam

View Details
  • Is 18 years of age or older
  • Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD
  • Has treated hypertension on stable therapy with at least 2 standard of care antihypertensive medications, one of which must be a thiazide, thiazide-like, or loop diuretic
Coronary artery with imaging scan illustration

CAD / Diagnostic Imaging

TRANSFORM Trial – Personalized Heart Disease Care

PROBE | Cleerly Inc

View Details
  • Men > 55 years of age, Women > 65 years of age or older
  • Type 2 diabetes, pre-diabetic or metabolic syndrome
  • No recent imaging for cardiovascular disease
  • No active symptomatic cardiovascular disease
Artery cross-section with plaque and catheter illustration

Vascular / PAD

Golazo® – Peripheral Atherectomy System Study

Device Trial | Nipro Vascular

View Details
  • Age ≥18 with PAD symptoms (Rutherford category 3–5)
  • Objective ABI/TBI criteria and angiographic lesion specifics
  • Must be a suitable candidate for angiography and endovascular intervention
LDL cholesterol particle illustration

Cardiology / Lipid Lowering

VictORION INTERVENTION Cardiovascular Outcomes

Phase IV | Novartis

View Details
  • Are 18 years of age or older and have recently undergone a coronary or peripheral vascular intervention (PCI or PVI)
  • Have a history of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease (CAD) or peripheral artery disease (PAD)
  • Have elevated LDL (‘bad’) cholesterol levels despite current cholesterol-lowering therapy